Baseline characteristics and hematologic variables of patient study
| Subject code . | Sex . | Age . | Subject class . | Diagnosis and genetics . | Prior treatment . | WBC . | RBC . | HBG . | HCT . | MCV . | PLT . | MPV . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103/μL . | 106/μL . | g/dL . | % . | fL . | 103/μL . | fL . | ||||||
| Con1 | F | 53 | Healthy control | None | None | 5.4 | 4.1 | 13.9 | 37.4 | 90.1 | 191 | 8.6 |
| Con2 | M | 31 | Healthy control | None | None | 9.2 | 4.7 | 15.7 | 43.2 | 91.2 | 333 | 8.7 |
| Con3 | F | 38 | Healthy control | None | None | 5.1 | 4.1 | 13.8 | 39.1 | 93.6 | 287 | 6.9 |
| Con4 | M | 27 | Healthy control | None | None | 5.8 | 5.6 | 17.5 | 47.5 | 85.9 | 150 | 8.5 |
| Con5 | F | 28 | Healthy control | None | None | 5.2 | 3.9∗ | 12.6 | 36.2 | 93.3 | 132∗ | 9.0 |
| Con6 | M | 32 | Healthy control | None | None | 9.8 | 4.8 | 15.1 | 41.9 | 88.1 | 256 | 8.6 |
| Pcv1 | F | 57 | Primary polycythemia | JAK2 mutation V617F | Periodic phlebotomy | 6.7 | 5.2 | 15.1 | 42.5 | 81.4 | 48∗ | 8.4 |
| Pcv2 | M | 70 | Primary polycythemia | Myeloproliferative syndrome; JAK2 negative | Periodic phlebotomy | 6.1 | 5.1 | 16.5 | 46.0 | 89.9 | 141∗ | 8.3 |
| Pcv3 | M | 61 | Primary polycythemia | JAK2 mutation V617F | Periodic phlebotomy + cytoreductive therapy | 8.4 | 4.1 | 16.5 | 44.6 | 109.1† | 332 | 7.9 |
| Pcv4 | F | 74 | Familial erythrocytosis | EGLN1 mutation (ECYT3) | Warfarin | 6.6 | 5.5 | 16.3 | 46.5 | 84.3 | 206 | 9.1† |
| Pcv5 | M | 65 | Primary polycythemia | JAK2 mutation V617F | Periodic phlebotomy + cytoreductive therapy | 8.4 | 4.1 | 15.6 | 43.5 | 104.8† | 281 | 7.9 |
| Ery1 | M | 68 | Primary erythrocytosis | PHD2 C127S, not pathogenetic Ongoing genotyping | Phlebotomy | 7.4 | 5.3 | 18.4† | 51.3 | 97.4† | 176 | 9.1† |
| Ery2 | M | 21 | Familial erythrocytosis | EPAS1 mutation (ECYT4) | Periodic phlebotomy | 6.3 | 5.6 | 18.2† | 48.8 | 86.5 | 164 | 7.9 |
| Ane1 | M | 55 | Anemia | GI bleeding in alcoholic liver failure | None | 4.8 | 1.9∗ | 6.9∗ | 18.5∗ | 97.7† | 81∗ | 8.5 |
| Ane2 | F | 57 | Anemia | Myeloid leukemia after chemotherapy | None | 0.2∗ | 1.8∗ | 6.2∗ | 16.2∗ | 90.4 | 15∗ | 7.5 |
| Ane3 | M | 67 | Anemia | Sepsis in acute cholecystitis | None | 5.0 | 2.6∗ | 6.3∗ | 18.0∗ | 70.2∗ | 256 | 8.0 |
| Ane4 | M | 79 | Anemia | Refractory anemia | None | 4.7 | 2.1∗ | 7.2∗ | 19.9∗ | 92.9 | 223 | 10.1† |
| Ane5 | F | 95 | Anemia | Gl bleeding and malnutrition | None | 6.3 | 1.3∗ | 4.5∗ | 12.0∗ | 95.8 | 149∗ | 8.0 |
| Ane6 | M | 91 | Chronic anemia | Chronic GI bleeding | None | 5.3 | 2.4∗ | 6.8∗ | 18.8∗ | 79.6 | 223 | 7.6 |
| Ane7 | M | 46 | Sickle cell anemia | Homozygous sickle cell disease | None | 13.2† | 2.4∗ | 9.1∗ | 24.6∗ | 103.8† | 282 | 7.2 |
| Ane8 | M | 84 | Hemolytic anemia | Immune hemolytic anemia | None | 7.4 | 2.1∗ | 6.4∗ | 18.2∗ | 87.7 | 67∗ | nd |
| Normal range | 4-10 | 4.0-5.8 | 12.0-18.0 | 35.0-52.0 | 79.0-96.0 | 150- 400 | 5.0-9.0 |
| Subject code . | Sex . | Age . | Subject class . | Diagnosis and genetics . | Prior treatment . | WBC . | RBC . | HBG . | HCT . | MCV . | PLT . | MPV . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103/μL . | 106/μL . | g/dL . | % . | fL . | 103/μL . | fL . | ||||||
| Con1 | F | 53 | Healthy control | None | None | 5.4 | 4.1 | 13.9 | 37.4 | 90.1 | 191 | 8.6 |
| Con2 | M | 31 | Healthy control | None | None | 9.2 | 4.7 | 15.7 | 43.2 | 91.2 | 333 | 8.7 |
| Con3 | F | 38 | Healthy control | None | None | 5.1 | 4.1 | 13.8 | 39.1 | 93.6 | 287 | 6.9 |
| Con4 | M | 27 | Healthy control | None | None | 5.8 | 5.6 | 17.5 | 47.5 | 85.9 | 150 | 8.5 |
| Con5 | F | 28 | Healthy control | None | None | 5.2 | 3.9∗ | 12.6 | 36.2 | 93.3 | 132∗ | 9.0 |
| Con6 | M | 32 | Healthy control | None | None | 9.8 | 4.8 | 15.1 | 41.9 | 88.1 | 256 | 8.6 |
| Pcv1 | F | 57 | Primary polycythemia | JAK2 mutation V617F | Periodic phlebotomy | 6.7 | 5.2 | 15.1 | 42.5 | 81.4 | 48∗ | 8.4 |
| Pcv2 | M | 70 | Primary polycythemia | Myeloproliferative syndrome; JAK2 negative | Periodic phlebotomy | 6.1 | 5.1 | 16.5 | 46.0 | 89.9 | 141∗ | 8.3 |
| Pcv3 | M | 61 | Primary polycythemia | JAK2 mutation V617F | Periodic phlebotomy + cytoreductive therapy | 8.4 | 4.1 | 16.5 | 44.6 | 109.1† | 332 | 7.9 |
| Pcv4 | F | 74 | Familial erythrocytosis | EGLN1 mutation (ECYT3) | Warfarin | 6.6 | 5.5 | 16.3 | 46.5 | 84.3 | 206 | 9.1† |
| Pcv5 | M | 65 | Primary polycythemia | JAK2 mutation V617F | Periodic phlebotomy + cytoreductive therapy | 8.4 | 4.1 | 15.6 | 43.5 | 104.8† | 281 | 7.9 |
| Ery1 | M | 68 | Primary erythrocytosis | PHD2 C127S, not pathogenetic Ongoing genotyping | Phlebotomy | 7.4 | 5.3 | 18.4† | 51.3 | 97.4† | 176 | 9.1† |
| Ery2 | M | 21 | Familial erythrocytosis | EPAS1 mutation (ECYT4) | Periodic phlebotomy | 6.3 | 5.6 | 18.2† | 48.8 | 86.5 | 164 | 7.9 |
| Ane1 | M | 55 | Anemia | GI bleeding in alcoholic liver failure | None | 4.8 | 1.9∗ | 6.9∗ | 18.5∗ | 97.7† | 81∗ | 8.5 |
| Ane2 | F | 57 | Anemia | Myeloid leukemia after chemotherapy | None | 0.2∗ | 1.8∗ | 6.2∗ | 16.2∗ | 90.4 | 15∗ | 7.5 |
| Ane3 | M | 67 | Anemia | Sepsis in acute cholecystitis | None | 5.0 | 2.6∗ | 6.3∗ | 18.0∗ | 70.2∗ | 256 | 8.0 |
| Ane4 | M | 79 | Anemia | Refractory anemia | None | 4.7 | 2.1∗ | 7.2∗ | 19.9∗ | 92.9 | 223 | 10.1† |
| Ane5 | F | 95 | Anemia | Gl bleeding and malnutrition | None | 6.3 | 1.3∗ | 4.5∗ | 12.0∗ | 95.8 | 149∗ | 8.0 |
| Ane6 | M | 91 | Chronic anemia | Chronic GI bleeding | None | 5.3 | 2.4∗ | 6.8∗ | 18.8∗ | 79.6 | 223 | 7.6 |
| Ane7 | M | 46 | Sickle cell anemia | Homozygous sickle cell disease | None | 13.2† | 2.4∗ | 9.1∗ | 24.6∗ | 103.8† | 282 | 7.2 |
| Ane8 | M | 84 | Hemolytic anemia | Immune hemolytic anemia | None | 7.4 | 2.1∗ | 6.4∗ | 18.2∗ | 87.7 | 67∗ | nd |
| Normal range | 4-10 | 4.0-5.8 | 12.0-18.0 | 35.0-52.0 | 79.0-96.0 | 150- 400 | 5.0-9.0 |
GI, gastrointestinal; HBG, hemoglobin; HCT, hematopoietic cell transplant; MCV, mean corpuscular volume; MPV, mean platelet volume; nd, not defined; PLT, platelet; WBC, white blood cell.
The bold values indicate values below or above the normal range. Values below normal ranges are marked with ∗, and those above normal ranges are marked with †.